이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Catalyst Pharmaceuticals 관리

관리 기준 확인 2/4

Catalyst Pharmaceuticals' CEO는 Rich Daly, Jan2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 3.52M 가치에 해당하는 회사 주식의 0.2% 직접 소유합니다. 3.52M. 경영진과 이사회의 평균 재임 기간은 각각 3.5 년과 11.5 년입니다.

주요 정보

Rich Daly

최고 경영자

US$14.1m

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.2%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	11.5yrs

최근 관리 업데이트

Recent updates

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

CEO

Rich Daly (63 yo)

less than a year

테뉴어

US$14,076,923

보상

Mr. Richard John Daly, also known as Rich, MBA, had been an Independent Director at Catalyst Pharmaceuticals, Inc. from February 2015 until January 1, 2024 and serves as its Chief Executive Officer and Dir...

리더십 팀

이름	위치	테뉴어	보상	소유권
Richard John Daly	President	less than a year	US$14.08m	0.20% $ 3.5m
Steven Miller	Executive VP	14.7yrs	US$3.40m	0.70% $ 12.4m
Gary Ingenito	Chief Medical & Regulatory Officer	9yrs	US$2.37m	0.044% $ 775.0k
Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	4yrs	US$2.51m	0.016% $ 277.9k
Michael Kalb	Executive VP	less than a year	데이터 없음	데이터 없음
Mary Coleman	VP & Head of Investor Relations	2.8yrs	데이터 없음	데이터 없음
Brian Elsbernd	Chief Compliance Officer & Chief Legal Officer	8.3yrs	US$353.27k	0.11% $ 1.9m
Pete Curry	Vice President of Sales	4yrs	데이터 없음	데이터 없음
Stanley Iyadurai	Senior Vice President of Medical Affairs & Drug Discovery	1.3yrs	데이터 없음	데이터 없음
Preethi Sundaram	Chief Strategy Officer	2.9yrs	US$1.70m	0.022% $ 385.1k
Philip Schwartz	Corporate Secretary	no data	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: CPRX 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard John Daly	President	9.3yrs	US$14.08m	0.20% $ 3.5m
David Tierney	Independent Director	21.7yrs	US$370.99k	0.30% $ 5.3m
Patrick McEnany	Co-Founder & Chairman	22.4yrs	US$2.15m	3.83% $ 68.3m
Donald Denkhaus	Independent Director	9.3yrs	US$376.24k	0.37% $ 6.6m
Charles O'Keeffe	Lead Independent Director	19.5yrs	US$397.24k	0.58% $ 10.3m
Eugene Laska	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Robert Fechtner	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jonathan Brodie	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Molly Harper	Independent Director	3yrs	US$363.12k	0% $ 0
Richard Silverman	Member of Scientific Advisory Board	13.6yrs	데이터 없음	데이터 없음
Tamar Thompson	Independent Director	1.1yrs	US$610.43k	데이터 없음

11.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: CPRX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.5 년).

Catalyst Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Insider recently sold US$411k worth of stock

Co-Founder exercised options to buy US$4.3m worth of stock.

COO & Chief Scientific Officer recently sold US$570k worth of stock

Recent updates

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS exceeds analyst expectations

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Catalyst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 15, 2023

Investor sentiment deteriorates as stock falls 30%

Investor sentiment improved over the past week

Chief Medical & Regulatory Officer exercised options and sold US$100k worth of stock

Chief Accounting Officer recently sold US$2.0m worth of stock

Independent Director recently sold US$332k worth of stock

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Price target increased to US$18.10

Price target increased to US$18.10

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Price target increased to US$17.30

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Catalyst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse(R) Expanding Patient Population to Include Pediatric Patients

Chief Accounting Officer recently sold US$714k worth of stock